In yesterday’s Wall Street session, FibroGen Inc. (NASDAQ:FGEN) shares traded at $1.37, down -4.86% from the previous session.
7 analysts cover FibroGen Inc. (NASDAQ:FGEN), according to research data. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $37.20 and a low of $2.00, we find $3.00. Given the previous closing price of $1.44, this indicates a potential upside of 108.33 percent. FGEN stock price is now -82.85% away from the 50-day moving average and -91.35% away from the 200-day moving average. The market capitalization of the company currently stands at $131.62M.
The stock has received a hold rating from 5 analysts and a buy rating from 0. Brokers who have rated the stock have averaged $11.14 as their price target over the next twelve months.
With the price target reduced from $4 to $2, BofA Securities Downgraded its rating from Neutral to Underperform for FibroGen Inc. (NASDAQ: FGEN).
In other news, Henderson Jeffrey William, Director sold 2,000 shares of the company’s stock on Aug 04. The stock was sold for $3,820 at an average price of $1.91. Upon completion of the transaction, the Director now directly owns 30,866 shares in the company, valued at $42286.42. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 11, Director Henderson Jeffrey William sold 2,000 shares of the business’s stock. A total of $5,380 was realized by selling the stock at an average price of $2.69. This leaves the insider owning 32,866 shares of the company worth $45026.42. Insiders disposed of 274,020 shares of company stock worth roughly $0.38 million over the past 1 year. A total of 0.90% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in FGEN stock. A new stake in FibroGen Inc. shares was purchased by ARTISAN PARTNERS LIMITED PARTNERSHIP during the first quarter worth $1,851,000. EVENTIDE ASSET MANAGEMENT, LLC invested $1,315,000 in shares of FGEN during the first quarter. In the first quarter, VOLORIDGE INVESTMENT MANAGEMENT, LLC acquired a new stake in FibroGen Inc. valued at approximately $444,000. PRUDENTIAL FINANCIAL INC acquired a new stake in FGEN for approximately $318,000. HRT FINANCIAL LP purchased a new stake in FGEN valued at around $265,000 in the second quarter. In total, there are 245 active investors with 78.70% ownership of the company’s stock.
On Wednesday morning FibroGen Inc. (NASDAQ: FGEN) stock kicked off with the opening price of $1.4750. During the past 12 months, FibroGen Inc. has had a low of $1.41 and a high of $25.69. The fifty day moving average price for FGEN is $7.6838 and a two-hundred day moving average price translates $15.7718 for the stock.
The latest earnings results from FibroGen Inc. (NASDAQ: FGEN) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.9, missing analysts’ expectations of -$0.7 by -0.2. This compares to -$0.78 EPS in the same period last year. The company reported revenue of $44.32 million for the quarter, compared to $29.81 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 48.69 percent. For the current quarter, analysts expect FGEN to generate $36.93M in revenue.
